The first vaccine against cancer has become a dream about to come true.. This is what the American company “Moderna” heralded, noting that its vaccine against cancer had obtained approval from the World Health Organization, describing this step as “advanced” towards finding an effective treatment for the malignant disease.
According to the British “Daily Mail” newspaper, the new vaccine is prescribed, along with an immunotherapy drug, for patients recovering from advanced skin cancer and at risk of recurrence of tumors.
As the Phase II trial showed that the combination reduces the chance of relapse or death in patients after surgery by 44%, compared to the immunotherapy drug alone, the promising results prompted the “Food and Drug Administration” (FDA) to issue its approval in a way that gives the opportunity to transfer the meeting to the market within A period of 8 months, and it becomes officially approved in the treatment of serious cases.
related topics
vaccine components
The “Sciences of Translational Medicine” journal stated that the experimental treatment is compatible with Corona vaccines, as the promising vaccine relies on the sent nucleic acid (mRNA) produced by the Moderna company, in conjunction with taking the immunotherapy drug “Keytruda” produced by the German company “Merck”.
Its mechanism of action takes place by vaccinating the body with a percentage of the virus’s DNA, so the body translates it and produces proteins that create autoimmunity for the body against this virus, which provides the body with a stronger response if it encounters the virus in the future.
In a cancer vaccine, mRNA encodes tumour-specific mutations called neoantigens. The body makes copies of these new antigens, learns to recognize them, and creates more immune cells that can target infected cells, thus fighting cancer.
Expensive complex process
In turn, the “National Cancer Institute (CDC) revealed that the production of the vaccine takes place individually, meaning that the vaccine differs from one patient to another, despite the adoption of the same mechanism, that is, samples are collected from the patient’s tissues, and then the DNA sent from them is extracted to start work on producing a vaccine, It is a process that takes between one and two months, and costs $100,000 per person.
Necessary experiences
However, most drugs or vaccines need to pass the third phase of trials before they are approved for widespread use, except in special circumstances, as happened during the Corona outbreak, when it was found that the vaccine was safe in the first and second phases of the trials, so it was approved.
According to the British newspaper, the two companies, “Merck” and “Moderna”, announced that they plan to start studying the third phase of treatment during 2023, so that it will be tested on thousands of patients, and it will also be expanded to see if the vaccine can be applied to other cancers, such as lung cancer with double Non-small cells, for example.
And in the event that the final result is reached, the treatment mechanism will be divided into 9 doses every 3 weeks, in addition to one dose of “Keytruda” every three weeks.
High injury rate
And the “American Cancer Society” announced last year that skin cancer rates have increased significantly over the past years, as 99 thousand and 780 cases were diagnosed during 2022, 57 thousand and 180 men, and 42 thousand and 600 women, and this is in the United States of America only.
While skin cancer is currently the most common among men, under the age of 50 it is more prevalent in women, and it is medically possible that 7650 people will die from skin cancer (5080 men and 2570 women).
The association revealed that the probability of developing skin cancer increases by more than 20 times for white people, compared to black and dark-skinned people, as the lifetime risk of developing skin cancer is 2.6% (one in 38) for whites, and 0.1% (one in 1000). ) for blacks, and 0.6% (1 in 167) for people of color.
Responsibility for the news: Cedar News is not responsible for this news in form or content, and it only expresses the point of view of its source or writer.